Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | VHL | P40337 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20997178 | 0.85 | ALDH1A1 (0.41) | CCNE1CDK2ALDH1A1GAAMAPT | |
| SCHEMBL22916939 | 0.83 | VHL (0.41) | CCNE1CDK2VHLALDH1A1GAA | |
| SCHEMBL27048554 | 0.80 | CCNE1 (0.35) | CCNE1CDK2HTTCYP19A1 | |
| SCHEMBL14262395 | 0.80 | CYP19A1 (0.37) | CCNE1CDK2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL23308741 | 0.79 | CCNE1 (0.38) | CCNE1CDK2ALDH1A1GAAMAPT | |
| SCHEMBL16674191 | 0.79 | CYP1A2 (0.41) | CCNE1CDK2ALDH1A1HTTCYP19A1 | |
| SCHEMBL26225463 | 0.76 | CCNE1 (0.34) | CCNE1CDK2ALDH1A1GAAMAPT | |
| SCHEMBL25859567 | 0.76 | VHL (0.41) | CCNE1CDK2VHLALDH1A1GAA | |
| SCHEMBL20997046 | 0.74 | PARP14 (0.41) | KDM4ELMNA | |
| SCHEMBL27048556 | 0.74 | CYP19A1 (0.46) | KMT2ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | CCNE1 27/4885CDK2 290/4885VHL 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.